title: Risk stratification after hospitalization for decompensated heart failure.
abstract: BACKGROUND
  Decompensated heart failure (HF) is among the most common indications for hospitalization in the United States, but little is known about features on admission that predict adverse events. We used data from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study to develop a model that would predict outcomes in patients with decompensated HF.
  
  
  RESULTS
  OPTIME-CHF randomized 949 patients hospitalized with decompensated HF for 48 to 72 hours of infusion of either milrinone or placebo. We used multivariable modeling to evaluate variables on admission that would be predictive of 60-day mortality or the composite of death or rehospitalization at 60 days. Variables at presentation that predicted death at 60 days were increased age, lower systolic blood pressure, New York Heart Association class IV symptoms, elevated blood urea nitrogen (BUN), and decreased sodium. Predictors of the composite of death or rehospitalization within 60 days were the number of HF hospitalizations in the preceding 12 months, elevated BUN, lower systolic blood pressure, decreased hemoglobin, and a history of percutaneous coronary intervention (PCI). The discriminatory power of the model was substantial for the mortality model (c-index .77) but less for the composite endpoint (c-index .69).
  
  
  CONCLUSIONS
  Risk stratification of patients with decompensated HF may be accomplished using easily assessed clinical variables. Further research into the validity of this model in independent samples will potentially aid in the development of risk stratification strategies.
authors.affiliation: Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA.
authors.forename: G Michael
authors.initials: GM
authors.lastname: Felker
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Leimberger
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
authors.forename: Michael S
authors.initials: MS
authors.lastname: Cuffe
authors.forename: Barry M
authors.initials: BM
authors.lastname: Massie
authors.forename: Kirkwood F
authors.initials: KF
authors.lastname: Adams
authors.forename: Mihai
authors.initials: M
authors.lastname: Gheorghiade
authors.forename: Christopher M
authors.initials: CM
authors.lastname: O'Connor
mesh_terms: D000368:Aged; D002316:Cardiotonic Agents / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000453:epidemiology* / Q000401:mortality; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D020105:Milrinone / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment
chemical_list: D002316:Cardiotonic Agents; D020105:Milrinone